SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com - UBS has reiterated its Buy rating on Bio-Rad Labs (NYSE:BIO) with a price target of $325.00, citing margin expansion opportunities and product cycles as key factors supporting the positive outlook. Currently trading at $291.97, the stock has analyst targets ranging from $265 to $409, with InvestingPro data showing the company is currently undervalued based on its Fair Value model.
The research firm highlighted Bio-Rad’s droplet digital PCR (ddPCR) business, which represents approximately 10% of the company’s projected fiscal year 2024 sales, following a company-hosted webinar on Wednesday. The company maintains strong financial health with a current ratio of 5.12 and operates with moderate debt levels.
UBS noted that Bio-Rad management has adjusted growth expectations for the ddPCR segment, now emphasizing "durable high-single-digit growth potential" rather than positioning it as minimally penetrated within a $10 billion total addressable market, as previously stated at the February 2022 analyst day.
The analyst firm described this revised growth outlook as "more reasonable" while still supporting the ddPCR business’s potential to contribute accretively to Bio-Rad’s overall growth story.
The webinar specifically addressed investor concerns about increasing competition and challenging demand conditions in the ddPCR market, with Bio-Rad showcasing its comprehensive portfolio and value proposition in this segment.
In other recent news, Bio-Rad Laboratories Inc . reported impressive financial results for the second quarter of 2025. The company achieved earnings per share of $2.61, significantly surpassing the analysts’ forecast of $1.73 by 50.87%. Revenue also exceeded expectations, reaching $651.6 million compared to the anticipated $615.2 million. These results underscore Bio-Rad’s strong performance in the quarter. Despite the positive earnings and revenue figures, the company’s stock experienced a decline in aftermarket trading, reflecting broader market trends and specific challenges facing the company. There were no updates regarding mergers or acquisitions during this period. Additionally, there were no recent analyst upgrades or downgrades reported for Bio-Rad Laboratories. Investors are likely to keep an eye on how the company navigates the current market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.